Found 3 results

Sort by: Author [ Title  (Desc)] Type Year
Filters: First Letter Of Title is P  [Clear All Filters]
A B C D E F G H I J K L M N O [P] Q R S T U V W X Y Z   [Show ALL]
Muema SM, Abuga KO, Yenesew A, Thoithi GN. "Phytochemical and Anthelmintic Study of the Root Bark of Teclea Trichocarpa, Engl. (Rutaceae)." East Cent. Afr. J. Pharm.. 2014;17(2):44-47. Abstract

The root bark of Teclea trichocarpa exhibited anthelmintic activity against egg hatching and larval development of sheep nematodes (Strongyloides). Three compounds, namely lupeol, melicopicine and 6-methoxytecleanthine were isolated from the dichloromethane-methanol (50:50) extract of the plant. Melicopicine and 6-methoxytecleanthine exhibited mild anthelmintic activity. The present study lends scientific credence to the traditional use of Teclea trichocarpa in the treatment of human helminth infections.

Manani RO, Abuga KO, Chepkwony HK. "Pharmaceutical Equivalence of Clarithromycin Oral Dosage Forms Marketed in Nairobi County, Kenya." Scientia Pharmaceutica. 2017;85(2):20. Abstract

Clarithromycin is a broad-spectrum semi-synthetic macrolide indicated for treatment of pneumonias, Helicobacter pylori, and chlamydial and skin infections. The object of this study was to evaluate the pharmaceutical equivalence of 14 generic clarithromycin products marketed in Nairobi County, Kenya, to the innovator products, using in vitro dissolution profiles and similarity factors (f2). Further, dissolution profiles of four innovator formulations manufactured in different sites were compared. Fourteen clarithromycin tablets/capsules and four suspensions were subjected to assay and comparative dissolution runs at pH 1.2, 4.5 and 6.8, for 60 and 90 min, respectively. All products complied with pharmacopoeial assay specifications. However, significant differences were observed in their dissolution profiles. The non-compliance rates for tablets/capsules were 50% at pH 1.2, 33% at pH 4.5 and 50% at pH 6.8, while none of the four suspensions were compliant. Overall, only four (25%) products complied with the specifications for similarity factor. The results obtained indicate that a significant percentage of generic clarithromycin products are pharmaceutically non-equivalent to the innovator products, and that assay and single-point dissolution tests are insufficient demonstration of equivalence between the generic and innovator products.

UoN Websites Search